TScan Therapeutics, Inc.

TCRXSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1783328

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$2.8M	$21.0M	$13.5M	$10.1M	$1.1M
Research and Development Expense	$107.3M	$88.2M	$59.8M	$45.0M	$20.6M
Operating Expenses	$137.6M	$114.5M	$80.2M	$58.8M	$27.3M
Operating Income (Loss)	-$134.8M	-$93.5M	-$66.6M	-$48.6M	-$26.2M
Interest Expense	$3.7M	$3.8M	$1.2M	$1.2M	—
Other Nonoperating Income (Expense)	$7.3M	$4.2M	$415.0K	$16.0K	—
Income Tax Expense (Benefit)	$0.00	—	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$371.1M	$272.1M	$199.1M	$188.1M	$49.7M
Assets, Current	$292.7M	$194.2M	$124.1M	$165.7M	$36.4M
Cash and Cash Equivalents, at Carrying Value	$178.7M	$133.4M	$120.0M	$161.4M	$34.8M
Liabilities	$130.1M	$121.3M	$99.7M	$27.3M	$32.5M
Liabilities, Current	$36.0M	$29.8M	$17.3M	$21.3M	$17.4M
Long-term Debt	$32.5M	$32.1M	$30.0M	$29.3M	—
Accounts Payable, Current	$4.3M	$2.4M	$2.9M	$1.8M	$2.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$110.8M	-$61.4M	-$66.5M	-$48.7M	-$3.0M
Net Cash Provided by (Used in) Investing Activities	-$52.6M	-$60.8M	-$4.2M	-$9.9M	-$4.2M
Net Cash Provided by (Used in) Financing Activities	$208.8M	$135.4M	$29.4M	$189.7M	$288.0K
Payments to Acquire Property, Plant, and Equipment	$3.8M	$3.1M	$4.2M	$9.9M	$4.2M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)